Nuveen
DFTX

Nuveen’s Definium Therapeutics DFTX Stock Holding History

Nuveen’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52M Buy
1,105,314
+407,184
+58% +$10.1M 0.01% 686
2026
Q1 		$13.2M Buy
698,130
+421,676
+153% +$7.16M ﹤0.01% 1393
2025
Q4 		$3.7M Buy
276,454
+42,950
+18% +$532K ﹤0.01% 2039
2025
Q3 		$2.75M Sell
233,504
-6,338
-3% -$59.1K ﹤0.01% 2164
2025
Q2 		$1.56M Sell
239,842
-26,209
-10% -$172K ﹤0.01% 2412
2025
Q1 		$1.56M Sell
266,051
-20,283
-7% -$145K ﹤0.01% 2445
2024
Q4 		$1.99M Buy
286,334
+8,856
+3% +$60.9K ﹤0.01% 2387
2024
Q3 		$1.58M Buy
277,478
+73,338
+36% +$510K ﹤0.01% 2537
2024
Q2 		$1.47M Buy
+204,140
New +$1.79M ﹤0.01% 2531

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nuveen's DFTX Position: Q2 2026 in Review

Nuveen increased its Definium Therapeutics (DFTX) stake by 58% in Q2 2026, buying an estimated $10.1M and bringing the position to 1,105,314 shares worth $52M. The position accounts for 0.01% of the portfolio, ranked #686.

Nuveen first reported a position in DFTX in Q2 2024 and has held it in 9 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Nuveen held 1,105,314 shares of Definium Therapeutics worth $52M as of Q2 2026.
  • Nuveen bought 407,184 Definium Therapeutics shares in Q2 2026, an estimated $10.1M.
  • Definium Therapeutics made up 0.01% of Nuveen's portfolio in Q2 2026, its #686 holding.
  • Nuveen first reported a position in Definium Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.